Summary
A Phase IIb, double-blind, randomized, parallel-group, placebo-controlled study to evaluate the safety, tolerability and efficacy of Study Drug in adults with chronic hepatitis C virus infection.
Register to download
PRA Exceeds Tough Enrollment Goals
You may also be interested in:
White Paper
Multi-Stakeholder Collaborations Can Minimize Barriers & Drive Rare Disease Clinical Programs to Better Patient Outcomes
Conducting clinical trials in rare diseases and advancing research pipelines requires a collaborative, multi-stakeholder approach. This process…
View Resource
Page
Pharmacovigilance & Patient Safety
Clinical trial participants help us speed breakthroughs in modern drug development. Our job is to protect them.
Read More
Case Study
PRA’s Unique Model Leads to Client Satisfaction
A randomized, multi-center, double-blind study to compare the efficacy and safety of Study Drug A and Study Drug B as monotherapy in newly diagnosed…
View Resource
View all related content and resources for Patient Recruitment and Retention
Explore Insights